Item 2.02 Results of Operations and Financial Condition.
The information provided in Item 7.01 of this Current Report on Form 8-K is
incorporated by reference into this Item 2.02.
Item 7.01 Regulation FD Disclosure.
On January 13, 2022, Landos Biopharma, Inc. (the “Company”) announced that its
estimated cash, cash equivalents and short-term investments balance as of
December 31, 2021 was approximately $91.0 million.
The Company’s estimate of its cash position is preliminary and unaudited,
represents management estimates as of the date of this Current Report on Form
8-K and are subject to completion of the Company’s financial closing procedures.
As a result, the Company’s actual financial results may differ materially from
the preliminary estimated financial information set forth above. The Company’s
independent registered public accounting firm has not conducted an audit or
review of, and does not express an opinion or any other form of assurance with
respect to, the estimate of the Company’s cash position.
The information in this Item 7.01 of this Current Report on Form 8-K is being
furnished and shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference in such a
Any statements in this report about future expectations, plans and prospects for
the Company and other statements containing the words “anticipate,” “estimate,”
“expect,” “may,” “will,” and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important factors, including
whether the Company identifies items during its financial statement closing
process that result in adjustments to the estimates, preliminary figures and
guidance included in this report and other factors discussed in the “Risk
Factors” section of the Company’s most recent Form 10-K or Form 10-Q filed with
the SEC and in the Company’s other filings from time to time with the SEC. In
addition, the forward-looking statements included in this report represent the
Company’s views as of the date hereof and should not be relied upon as
representing the Company’s views as of any date subsequent to the date hereof.
The Company anticipates that subsequent events and developments will cause the
Company’s views to change. However, while the Company may elect to update these
forward-looking statements at some point in the future, the Company specifically
disclaims any obligation to do so.
© Edgar Online, source Glimpses